<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">FUJITA, SHIRO</style></author><author><style face="normal" font="default" size="100%">MASAGO, KATSUHIRO</style></author><author><style face="normal" font="default" size="100%">SASAKI, EIICHI</style></author><author><style face="normal" font="default" size="100%">TSUKUSHI, SATOSHI</style></author><author><style face="normal" font="default" size="100%">HORIO, YOSHITSUGU</style></author><author><style face="normal" font="default" size="100%">KURODA, HIROAKI</style></author><author><style face="normal" font="default" size="100%">HIDA, TOYOAKI</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Weak-evidence Fusion Candidates Detected by a FusionPlex Assay Using the Ion Torrent System</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">993-998</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/invivo.12342</style></doi><volume><style face="normal" font="default" size="100%">35</style></volume><issue><style face="normal" font="default" size="100%">2</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: The Archer FusionPlex platform is widely used for comprehensive fusion-gene detection in cancer tissues. This platform separately displays results for strong-evidence and weak-evidence fusion candidates (WEFCs). Distinctive fusion patterns are frequently found in the weak-evidence category and information about the patterns is clinically essential. Patients and Methods: We describe the type and frequency of WEFCs observed using the FusionPlex Sarcoma Panel (S Panel) and the FusionPlex ALK, RET, and ROS1 ver2 Panel (ARR Panel). Results: A total of 97 specimens were examined and 620 candidates were detected and categorized as WEFCs. A median of five WEFCs were detected per sample. In the S Panel group, there were 13 WEFCs with a frequency of more than 1%. In the ARR Panel group, a total of 16 WEFCs were detected with a frequency of more than 1%. Conclusion: Specific WEFCs were detected according to the panel selected.</style></abstract></record></records></xml>